Recent developments for smoking cessation and treatment of nicotine dependence

Bibliography

• MUSK AW, DE KLERK NH: History of tobacco and health. Respirology (2003) 8:286-290.
   PubMed Web of Science ®Google Scholar
• COE JW, BROOKS PR, VETELINO MG et al.: Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. (2005) 48:3474-3477.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH, MITTA W, KUPERSMITH A, KEY T: Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol. Rev. (2006) 14:57-73.
   PubMedGoogle Scholar
• FOULDS J: The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. J. Clin. Pract. (2006): 60:571-576.
   Google Scholar
• NIDES M, ONCKEN C, GONZALES D et al.: Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Arch. Intern. Med. (2006) 166:1561-1568.
   PubMed Web of Science ®Google Scholar
• JENSEN AA, FRØLUND B, LILJEFORS T, KROGSGAARD-LARSEN P: Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J. Med. Chem. (2005) 48:4705-4745.
   PubMed Web of Science ®Google Scholar
• ABIN-CARRIQUIRY JA, VOUTILAINEN MH, BARIK J et al.: C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists. Eur. J. Pharmacol. (2006) 536:1-11.
   PubMed Web of Science ®Google Scholar
• COE JW, VETELINO MG, BASHORE CG et al.: In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg. Med. Chem. Lett. (2005) 15:2974-2979.
   PubMed Web of Science ®Google Scholar
• MORONI M, ZWART R, SHER E, CASSELS BK, BERMUDEZ I: α4β2 Nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol. Pharmacol. (2006) 70:755-768.
   PubMed Web of Science ®Google Scholar
• WOOLTORTON JR, PIDOPLICHKO VI, BROIDE RS, DANI JA: Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J. Neurosci. (2003) 23:3176-3185.
   PubMed Web of Science ®Google Scholar
• DANI JA: Roles of dopamine signaling in nicotine addiction. Mol. Psychiatry (2003) 8:255-256.
   Google Scholar
• WU J, LIU Q, YU K, HU J, KUO Y-P, SEGERBERG et al.: Roles of nicotinic acetylcholine receptor β subunits in function of human α4-containing nicotine receptors. J. Physiol. (2006) 576:103-118.
   Google Scholar
• LANGE JH, KRUSE CG. Medicinal chemical strategies to CB1 cannabinoid receptor antagonists. Drug Dicov. Today (2005) 10:693-702.
   PubMed Web of Science ®Google Scholar
• MALDONADO R, VALVERDE O, BERRENDERO F: Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. (2006) 29:225-232.
   PubMed Web of Science ®Google Scholar
• TUCCI SA, HALFORD JC, HARROLD JA, KIRKHAM TC: Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med. Chem. (2006) 13:2669-2680.
   PubMed Web of Science ®Google Scholar
• COHEN C, PERRAULT G, GRIEBEL G, SOUBRIE P: Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology (2005) 30:145-155.
   PubMed Web of Science ®Google Scholar
• REDDEN DT, SHIELDS PG, EPSTEIN L et al.: Catechol-O-methyl-transferase functional polymorphism and nicotine dependence: an evaluation of nonreplicated results. Cancer Epidemiol. Biomarkers Prev. (2005) 14:1384-1389.
   Google Scholar
• KHURANA S, BATRA V, PATKAR AA, LEONE FT: Twenty-first century tobacco use: it is not just a risk factor anymore. Respir. Med. (2003) 97:295-301.
   Google Scholar
• AUDRAIN-MCGOVERN J, AL KOUDSI N, RODRIGUEZ D, WILEYTO EP, SHIELDS PG, TYNDALE RF: The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics (2007) 119:e264-e274.
   PubMed Web of Science ®Google Scholar
• SWAN GE, VALDES AM, RING HZ et al.: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogen. J. (2005) 5:21-29.
   PubMed Web of Science ®Google Scholar
• BRODY AL, MANDELKERN MA, OLMSTEAD RE et al.: Gene variants of brain dopamine pathways and smoking- induced dopamine release in the ventral tegmental caudate/nucleus accumbens. Arch. Gen. Psychiatry (2006) 63:808-816.
   PubMed Web of Science ®Google Scholar
• COLILLA S, LERMAN C, SHIELDS PG et al.: Association of catechol-O-methyl- transferase with smoking cessation in two independent studies of women. Pharmacogenet. Genomics (2005) 15:393-398.
   PubMed Web of Science ®Google Scholar
• COFTA-WOERPEL L, WRIGHT KL, WETTER DW: Smoking cessation 1: pharmacological treatments. Behav. Med. (2006) 32:47-56.
   PubMed Web of Science ®Google Scholar
• MARLOW SP, STOLLER JK: Smoking cessation. Respir. Care (2003) 48:1238-1254.
   PubMedGoogle Scholar
• MACROBBIE H, LEE M, JUNIPER Z: Non-nicotine pharmacotherapies for smoking cessation. Respir. Med. (2005) 99:1203-1212.
   Google Scholar
• LAM CY, MINNIX JA, ROBINSON JD, CINCIRIPINI PM: A brief review of pharmacotherapies for smoking cessation. J. Natl. Compr. Netw. (2006) 4:583-589.
   Google Scholar
• RANNEY L, MELVIN C, LUX L, McCLAIN E, LOHR KN: Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann. Intern. Med. (2006) 145:845-856.
   PubMed Web of Science ®Google Scholar
• SCHNOLL RA, LERMAN C: Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin. Emerg. Drugs (2006) 11:429-444.
   PubMedGoogle Scholar
• JORENBY DE, HAYS JT, RIGOTTI NA et al.: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist vs. placebo or sustained-release bupropion for smoking cessation. JAMA (2006) 296:56-63.
   PubMed Web of Science ®Google Scholar
• BERRETTINI WH, WILEYTO EP, EPSTEIN L et al.: Cathecol-O-methyl- transferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol. Psychiatry (2007) 61:111-118.
   PubMed Web of Science ®Google Scholar
• FOULDS J, STEINBERG MB, WILLIAMS JM, ZIEDONIS DM: Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev. (2006) 25:59-71.
   PubMed Web of Science ®Google Scholar
• TONG EK, CARMODY TP, SIMON JA: Bupropion for smoking cessation: a review. Comp. Ther. (2006) 32:26-33.
   Google Scholar
• LEE AM, JEPSON C, HOFFMANN E et al.: CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol. Psychiatry (2007): Jan 12 [Epub ahead of print].
   Google Scholar
• SCHARF D, SCHIFFMAN S: Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of bupropion SR. Addiction (2004) 99:1462-1469.
   PubMed Web of Science ®Google Scholar
• DALE LC, GLOVER ED, SACHS DP et al.: Bupropion for smoking cessation: predictors of successful outcome. Chest (2001) 119:1357-1364.
   PubMed Web of Science ®Google Scholar
• ELS C: What is the role of pharmacotherapy in tobacco cessation in patients with schizophrenia? Rev. Psychiatr. Neurosci. (2004) 29:240.
   Google Scholar
• MUNAFO MR, ELLIOT KM, MURPHY MF, WALTON RT, JOHNSTONE EC: Association of the μ-opioid receptor gene with smoking cessation. Pharmacogenomics J. (2007) Jan 16 [Epub ahead of print].
   Google Scholar
• SHIELDS AE, BLUMENTHAL D, WEISS KB, COMSTOCK CB, CURRIVAN D, LERMAN C: Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J. Gen. Intern. Med. (2005) 20:131-138.
   Google Scholar
• DAVID S, LANCASTER T, STEAD LF: Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev. (2006) 4:CD003086.
   Google Scholar
• O’MALLEY SS, COONEY JL, KRISHNAN-SARIN S et al.: A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch. Intern. Med. (2006) 166:667-674.
   PubMed Web of Science ®Google Scholar
• KING A, DE WIT H, RILEY RC, CAO D, NIAURA R, HATSUKAMI D: Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob. Res. (2006) 8:671-682.
   PubMed Web of Science ®Google Scholar
• ETTER J-F: Cytisine for smoking cessation. Arch. Intern. Med. (2006) 166:1553-1559.
   PubMed Web of Science ®Google Scholar
• FITCH RW, KANEKO Y, KLAPERSKI P, DALY JW, SEITZ G, GÜNDISH D: Halogenated and isosteric derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors. Bioorg. Chem. Lett. (2005) 15:1221-1224.
   PubMed Web of Science ®Google Scholar
• SLATER YE, HOULIHAN LM, MASKELL PD et al.: Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology (2003) 44:503-515.
   PubMed Web of Science ®Google Scholar
• VARAS R, VALDÉS V, ITURRIAGA-VÁSQUES P, CASSELS BK, ITURRIAGA R, ALCAYAGA J: Electrophysiological characterization of nicotinic acetylcholine receptors in cat petrosal ganglion neurons in culture: effects of cytisine and its bromo derivatives. Brain Res. (2006) 1072:72-78.
   Google Scholar
• TUTKA P, ZATONSKI W: Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol. Rep. (2006) 58:777-798.
   PubMed Web of Science ®Google Scholar
• ZATONSKI W, CEDZYNSKA M, TUTKA P, WEST R: An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob. Control. (2006) 15:481-484.
   PubMed Web of Science ®Google Scholar
• OSTROVSKAYA TP: Clinical trial of antinicotine drug-containing films. Biomed. Eng. (1994) 28:168-171.
   Google Scholar
• HONDA T, TAKAHASHI R, NAMIKI H: Synthesis of (+)-cytisine, (-)-kuraramine, (-)-isokuraramine, and (-)-jussiaeiine A. J. Org. Chem. (2005) 70:499-504.
   Google Scholar
• CHELLAPPAN SK, XIAO Y, TUECKMANTEL W, KELLER KJ, KOZIKOWSKI AP: Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J. Med. Chem. (2006) 49:2673-2676.
   PubMed Web of Science ®Google Scholar
• COE JW, BROOKS PR, WIRTZ MC et al.: 3,5-Bicyclic aryl piperidines: a novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg. Med. Chem. Lett. (2005) 15:4889-4897.
   Google Scholar
• GONZALES D, RENNARD SI, NIDES M et al.: Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation. JAMA (2006) 296:47-55.
   PubMed Web of Science ®Google Scholar
• MIHALAK KB, CARROLL FI, LUETJE CW: Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol. Pharmacol. (2006) 70:801-805.
   PubMed Web of Science ®Google Scholar
• ONCKEN C, GONZALES D, NIDES M et al.: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. (2006) 166:1571-1577.
   PubMed Web of Science ®Google Scholar
• TONSTAD S, TONNESEN P, HAJEK P, WILLIAMS KE, BILLING CB, REEVES KR: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 296:64-71.
   PubMed Web of Science ®Google Scholar
• KEATING GM, SIDDIQUI MA: Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs (2005) 20:945-960.
   Google Scholar
• MUCCIOLI GG, LAMBERT DM: Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem. (2005) 12:1361-1394.
   PubMed Web of Science ®Google Scholar
• MAURER P, JENNINGS GT, WILLERS J et al.: A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. (2005) 35:2031-2040.
   PubMed Web of Science ®Google Scholar
• HATSUKAMI DK, RENNARD S, JORENBY D et al.: Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. (2005) 78:456-467.
   Google Scholar
• KANTAK KM: Vaccines against drugs of abuse: a viable option? Drugs (2003) 63:341-352.
   Google Scholar
• SCHROEDER SA, SOX HC: Trials that matter: varenicline: a designer drug to help smokers quit. Ann. Intern. Med. (2006) 145:784-785.
   Google Scholar